Market Closed -
Hong Kong S.E.
04:08:20 2024-04-26 am EDT
|
5-day change
|
1st Jan Change
|
1.08
HKD
|
-0.92%
|
|
-6.90%
|
-29.41%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
2,599
|
2,764
|
1,961
|
959.8
|
900.9
|
635.9
|
-
|
Enterprise Value (EV)
1 |
1,991
|
2,506
|
1,950
|
934
|
900.9
|
635.9
|
635.9
|
P/E ratio
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Yield
|
1.27%
|
1.23%
|
1.83%
|
1.23%
|
-
|
2.78%
|
-
|
Capitalization / Revenue
|
2.13
x
|
2.27
x
|
1.55
x
|
0.78
x
|
0.86
x
|
0.5
x
|
0.44
x
|
EV / Revenue
|
2.13
x
|
2.27
x
|
1.55
x
|
0.78
x
|
0.86
x
|
0.5
x
|
0.44
x
|
EV / EBITDA
|
13.2
x
|
9.85
x
|
0.88
x
|
4.2
x
|
-
|
2.63
x
|
6.17
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
1.14
x
|
1.29
x
|
0.8
x
|
0.5
x
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
587,920
|
588,125
|
588,835
|
588,835
|
588,835
|
588,835
|
-
|
Reference price
2 |
4.420
|
4.700
|
3.330
|
1.630
|
1.530
|
1.080
|
1.080
|
Announcement Date
|
3/26/20
|
3/30/21
|
3/29/22
|
3/30/23
|
3/26/24
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
1,219
|
1,217
|
1,266
|
1,233
|
1,053
|
1,278
|
1,461
|
EBITDA
1 |
196.2
|
280.6
|
2,216
|
228.8
|
-
|
241.4
|
103.1
|
EBIT
1 |
141.5
|
153.1
|
2,069
|
76.3
|
42.68
|
105
|
103.1
|
Operating Margin
|
11.61%
|
12.58%
|
163.4%
|
6.19%
|
4.05%
|
8.22%
|
7.05%
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
0.0560
|
0.0580
|
0.0610
|
0.0200
|
-
|
0.0300
|
-
|
Announcement Date
|
3/26/20
|
3/30/21
|
3/29/22
|
3/30/23
|
3/26/24
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
607
|
258
|
10.4
|
25.8
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
5.57%
|
5.82%
|
86.1%
|
2.34%
|
-
|
4.21%
|
3.99%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
3.880
|
3.660
|
4.190
|
3.270
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/26/20
|
3/30/21
|
3/29/22
|
3/30/23
|
3/26/24
|
-
|
-
|
Last Close Price
1.08
HKD Average target price
1
HKD Spread / Average Target -7.41% Consensus |
1st Jan change
|
Capi.
|
---|
| -29.41% | 81.24M | | +25.83% | 661B | | +27.00% | 566B | | -6.76% | 352B | | +20.34% | 332B | | +3.00% | 283B | | +13.09% | 231B | | +5.46% | 200B | | -9.61% | 195B | | -6.26% | 145B |
Other Pharmaceuticals
|